Skip to main content

Table 3 Table showing the mean cell survival as percent of the solvent control measured for the tested breast cancer cell lines according to the tested compounds ± standard deviation

From: Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids

Cell line

5-FU

Crbp

Doc

Pac

EC

EC-Doc

EC-Pac

DocAC

FEC

FEC-Doc

HCC1937

37.09 ± 1.92

80.95 ± 0.67

101.38 ± 2.69

93.37 ± 1.71

85.12 ± 5.26

87.57 ± 5.03

83.74 ± 10.44

75.06 ± 2.80

25.99 ± 4.12

22.56 ± 2.24

HCC1143

116.84 ± 13.72

104.71 ± 26.68

121.36 ± 45.60

81.97 ± 42.22

86.07 ± 24.99

117.00 ± 23.75

91.59 ± 33.35

97.56 ± 6.57

105.97 ± 20.15

115.57 ± 31.20

MCF7

63.77 ± 4.73

91.71 ± 13.55

81.80 ± 11.41

70.38 ± 5.01

90.96 ± 18.68

86.60 ± 15.68

59.78 ± 23.96

74.90 ± 16.61

68.40 ± 10.85

56.89 ± 13.37

T-47D

66.29 ± 2.38

nd

78.13 ± 7.33

75.83 ± 7.83

81.83 ± 7.13

70.33 ±

47.77 ± 8.98

49.88 ± 4.63

50.99 ± 10.40

nd

Mean

78.68

95.09

99.08

79.77

86.35

94.26

74.37

78.62

71.18

70.06

  1. HR hormone receptor, 5-FU 5-fluorouracil, Crbp carboplatin, Doc docetaxel, Pac paclitaxel, EC epirubicin + cyclophosphamide, DocAC docetaxel + doxorubicin + cyclophosphamide, FEC 5-fluorouracil + epirubicin + cyclophosphamide, nd not done